Literature DB >> 19628472

Pharmacokinetic interactions between rifabutin and lopinavir/ritonavir in HIV-infected patients with mycobacterial co-infection.

H Khachi, R O'Connell, D Ladenheim, C Orkin.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19628472     DOI： 10.1093/jac/dkp263

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN： 0305-7453            Impact factor:   5.790


× No keyword cloud information.
  15 in total

Review 1.  The challenge of new drug discovery for tuberculosis.

Authors:  Anil Koul; Eric Arnoult; Nacer Lounis; Jerome Guillemont; Koen Andries
Journal:  Nature       Date:  2011-01-27       Impact factor: 49.962

2.  The ethics of a clinical trial when the protocol clashes with international guidelines.

Authors:  N T N Lan; N T N Thu; N H Duc; N N Lan; T T X Lien; N H Dung; A-M Taburet; D Laureillard; L Borand; C Quillet; D Lagarde; A Pym; C Connolly; C Lienhardt; C Rekacewicz; A D Harries
Journal:  Public Health Action       Date:  2013-06-21

Review 3.  Initiating antiretrovirals during tuberculosis treatment: a drug safety review.

Authors:  Tanuja N Gengiah; Andrew L Gray; Kogieleum Naidoo; Quarraisha Abdool Karim
Journal:  Expert Opin Drug Saf       Date:  2011-01-05       Impact factor: 4.250

4.  Pharmacokinetics of darunavir/ritonavir and rifabutin coadministered in HIV-negative healthy volunteers.

Authors:  Vanitha Sekar; Ludo Lavreys; Tom Van de Casteele; Cindy Berckmans; Sabrina Spinosa-Guzman; Tony Vangeneugden; Martine De Pauw; Richard Hoetelmans
Journal:  Antimicrob Agents Chemother       Date:  2010-07-26       Impact factor: 5.191

Review 5.  Treatment optimization in patients co-infected with HIV and Mycobacterium tuberculosis infections: focus on drug-drug interactions with rifamycins.

Authors:  Mario Regazzi; Anna Cristina Carvalho; Paola Villani; Alberto Matteelli
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

6.  Factors influencing lopinavir and atazanavir plasma concentration.

Authors:  Wolfgang Stöhr; David Back; David Dunn; Caroline Sabin; Alan Winston; Richard Gilson; Deenan Pillay; Teresa Hill; Jonathan Ainsworth; Brian Gazzard; Clifford Leen; Loveleen Bansi; Martin Fisher; Chloe Orkin; Jane Anderson; Margaret Johnson; Philippa Easterbrook; Sara Gibbons; Saye Khoo
Journal:  J Antimicrob Chemother       Date:  2010-01       Impact factor: 5.790

7.  Pharmacokinetics of rifabutin in Japanese HIV-infected patients with or without antiretroviral therapy.

Authors:  Junko Tanuma; Kazumi Sano; Katsuji Teruya; Koji Watanabe; Takahiro Aoki; Haruhito Honda; Hirohisa Yazaki; Kunihisa Tsukada; Hiroyuki Gatanaga; Yoshimi Kikuchi; Shinichi Oka
Journal:  PLoS One       Date:  2013-08-05       Impact factor: 3.240

8.  Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort.

Authors:  Antonella Cingolani; Alessandro Cozzi-Lepri; Adriana Ammassari; Cristina Mussini; Maria Alessandra Ursitti; Pietro Caramello; Gioacchino Angarano; Paolo Bonfanti; Andrea De Luca; Maria Stella Mura; Enrico Girardi; Andrea Antinori; Antonela D'Arminio Monforte
Journal:  PLoS One       Date:  2014-02-27       Impact factor: 3.240

9.  Randomised pharmacokinetic trial of rifabutin with lopinavir/ritonavir-antiretroviral therapy in patients with HIV-associated tuberculosis in Vietnam.

Authors:  Nguyen Thi Ngoc Lan; Nguyen Thi Nguyet Thu; Aurélie Barrail-Tran; Nguyen Hong Duc; Nguyen Ngoc Lan; Didier Laureillard; Truong Thi Xuan Lien; Laurence Borand; Catherine Quillet; Catherine Connolly; Dominique Lagarde; Alexander Pym; Christian Lienhardt; Nguyen Huy Dung; Anne-Marie Taburet; Anthony D Harries
Journal:  PLoS One       Date:  2014-01-22       Impact factor: 3.240

Review 10.  Management of HIV-associated tuberculosis in resource-limited settings: a state-of-the-art review.

Authors:  Stephen D Lawn; Graeme Meintjes; Helen McIlleron; Anthony D Harries; Robin Wood
Journal:  BMC Med       Date:  2013-12-02       Impact factor: 8.775
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.